[424B3] Medicus Pharma Ltd. Prospectus Filed Pursuant to Rule 424(b)(3)

Rhea-AI Filing Summary

Medicus Pharma announced the appointment of Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025. The company filed a prospectus supplement regarding up to 3,710,000 common shares trading on Nasdaq under symbol MDCX at a last reported price of $2.49 on June 20, 2025.

Key details of Smith's appointment:

• Brings 30+ years of experience in asset management and financial operations
• Annual base salary: $325,000
• Stock option grant: 100,000 shares at $2.60 strike price, vesting quarterly over 5 years
• Previous roles include CEO of SR Asset Management and senior positions at Aberdeen Asset Management
• Holds Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce

The company is classified as an emerging growth company, eligible for reduced public company disclosure requirements. The filing includes standard risk disclaimers and confirms no reportable related-party transactions with Smith.

Positive

• Appointment of highly experienced COO Andrew Smith with over 30 years of leadership experience in asset management and financial operations
• New COO brings significant C-suite experience including roles as Chairman/CEO of SR Asset Management and senior positions at Aberdeen Asset Management
• Structured compensation package includes performance incentives with 100,000 stock options vesting over 5 years, aligning management interests with shareholders

Negative

• Stock price at $2.49 indicates significant decline from warrant exercise price of $4.64, suggesting market concerns about company valuation
• Company's emerging growth status may indicate limited operational history and higher investment risks

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-287582

PROSPECTUS SUPPLEMENT NO. 4

(to prospectus dated May 29, 2025)

Medicus Pharma Ltd.

Up to 3,710,000 Common Shares

This prospectus supplement amends and supplements the prospectus dated May 29, 2025, as supplemented or amended from time to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-287582). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 23, 2025 (the "Form 8-K"). Accordingly, we have attached the Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common shares are listed on The Nasdaq Capital Market ("Nasdaq") under the symbol "MDCX". On June 20, 2025, the last reported sales price of the common shares was $2.49.

We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" beginning on page 9 of the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.

None of the Securities and Exchange Commission, any state securities commission or the securities commission of any Canadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or the Prospectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 23, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario	001-42408	98-1778211
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant's telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which
				registered
Common shares, no par value		MDCX		NASDAQ Capital Market
Warrants, each exercisable for one		MDCXW		NASDAQ Capital Market
common share at an exercise price of
$4.64 per share

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO"). Mr. Smith first joined the Company as a consultant on May 27, 2025 and will transition to his new role as COO on or about June 30, 2025.

Mr. Smith joins the Company with over three decades experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Most recently, Mr. Smith served as a Consultant and Business Advisor to Connor Capital SB, LLC ("Connor Capital") from April 2024 to September 2024. Prior to joining Connor Capital, Mr. Smith served as the Chairman and Chief Executive Officer of SR Asset Management, LLC ("SRAM") from January 2017 until its sale in June 2024. Before joining SRAM, Mr. Smith held various leadership positions at Aberdeen Asset Management Inc. ("Aberdeen"), including as the Co-Head of Americas and Chief Operating Officer from 2014 to 2016, as Aberdeen's Chief Financial and Chief Operating Officer and as the Chief Compliance Officer for Aberdeen's North American Closed End Funds from 2005 until 2013, and as the Vice President of Finance & Administration from 2001 until 2004. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry. Mr. Smith holds an Executive MBA from INSEAD in Fountainebleau and received an HND in Accounting from Glasgow College of Commerce, Scotland.

The Company entered into an agreement with Mr. Smith to memorialize his employment (the "Employment Agreement"). Pursuant to the terms of the Employment Agreement, Mr. Smith will commence employment as COO on or about June 30, 2025. In this role, Mr. Smith will receive an annual base salary of $325,000. Mr. Smith will also receive a grant of 100,000 stock options covering shares of the Company common stock with a strike price of $2.60 per share, vesting quarterly over the next five years, subject to Mr. Smith's continued service to the Company through each vesting date.

There are no family relationships between Mr. Smith and any director or executive officer of the Company pursuant to Item 401(d) of Regulation S-K and the Company has not entered into any transactions with Mr. Smith that are reportable pursuant to Item 404(a) of Regulation S-K. Except as described above, there are no arrangements or understandings between Mr. Smith and any other persons pursuant to which he will be appointed as an executive officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.

By:	/s/ Raza Bokhari
Name:	Dr. Raza Bokhari
Title:	Executive Chairman and Chief Executive Officer

Dated: June 23, 2025

FAQ

Who is MDCX's new Chief Operating Officer and when does he start?

Andrew Smith, age 57, has been appointed as MDCX's new Chief Operating Officer. He will transition to the COO role on or about June 30, 2025, after initially joining the company as a consultant on May 27, 2025.

What is Andrew Smith's compensation package as MDCX's new COO?

Andrew Smith's compensation package includes an annual base salary of $325,000 and a grant of 100,000 stock options with a strike price of $2.60 per share. The stock options vest quarterly over five years, contingent on his continued service with the company.

What is MDCX's current stock price as of June 2025?

According to the filing, MDCX's last reported sales price on the Nasdaq Capital Market was $2.49 per share on June 20, 2025.

What is Andrew Smith's professional background before joining MDCX?

Smith has over 30 years of experience in asset management and financial operations. His previous roles include serving as Chairman and CEO of SR Asset Management (2017-2024), various leadership positions at Aberdeen Asset Management including Co-Head of Americas and COO (2014-2016), and CFO/COO roles from 2005-2013. He holds an Executive MBA from INSEAD and an HND in Accounting from Glasgow College of Commerce.

How many common shares is MDCX offering in this prospectus supplement?

The prospectus supplement covers up to 3,710,000 common shares of Medicus Pharma Ltd.